The Conference Chairs are delighted to announce the Oral Communication presenter winners who were selected from 45+ submitted works
SESSION 1 – Thursday 4 July
Treatments and New Drugs
ARINA-1 Demonstrates Improved Quality of Life in a Phase 2a, Randomized, Double-blind, Placebo-controlled Study in Individuals with Non-CF Bronchiectasis (NCFBE) with Excess Mucus and Cough (RVN-301) – George Solomon (USA)
Bronchiectasis
Cluster analysis identifies distinct sputum inflammatory profiles in bronchiectasis: data from the EMBARC-BRIDGE study – Emma Johnson (UK)
17.45 – 17.55
Bronchiectasis
The profile of blood methylation is associated with disease severity in bronchiectasis – Lidia Perea (Spain)
17.55 – 18.05
Radiological assessment of bronchial and arterial dimensions and mucus plug presence in 640 bronchiectasis patients: insights from the EMBARC registry – Yuxin Chen (The Netherlands)
SESSION 2 – Friday 5 July
08.30 – 08.40
Bronchiectasis
Highly symptomatic patients have an increased risk of exacerbations and benefit from long-term macrolide treatment in Bronchiectasis – Sibila Oriol (Spain)
08.40 – 08.50
NTM
Clinical characteristics, treatment, and outcomes of patients with M. avium complex pulmonary disease: results from the IRENE registry. – Stefano Aliberti (Italy)
08.50 – 09.00
NTM
Disease PhenotypeIn Bronchiectasis (Ntm-And Ntm+) Is Associated With Lower Airway Dysbiosis And Neutrophil Extracellular Traps – Shivani Singh(USA)
09.00 – 09.10
NTM
Mycobacterial drug tolerance assessments reveal clinical outcomes – Alexander Jovanovic(Switzerland)
Â
The abstract book and on-site information activities on abstracts will be supported by Educational Unrestricted grant of
